Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co.) and Opdivo (BMS), are commonly prescribed as monotherapy or in combination with CTLA-4 inhibitors (Yervoy, BMS) or LAG-3 inhibitors in a fixed dose combination (Opdualag, BMS). While these treatment options have historically demonstrated good efficacy outcomes, a substantial proportion of patients still do not benefit from these therapies. Additionally, the high rates of treatment-related adverse event and the associated discontinuation rate, particularly with the use of combinational approaches, further limit the use of those regimens. Currently, there is no established standard of care for patients progressing after an anti-PD-1 based therapy, leaving a large drug-treatable population with limited options, underscoring the pressing need for novel approaches in this setting.
QUESTIONS ANSWERED
- How satisfied are U.S. and European medical oncologists with the current treatment options for BRAF wild-type unresectable or metastatic malignant melanoma?
- Which clinical factors most strongly influence therapy selection for patients with BRAF wildtype unresectable or metastatic malignant melanoma?
- How are current treatments (immune checkpoint inhibitors; oncolytic viruses and adoptive cell therapies) performing in relation to treatment goals and unmet need?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new BRAF wild-type unresectable or metastatic malignant melanoma treatment opportunity?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European medical oncologists
Key drugs: Amtagvi, Imlygic, Keytruda, Opdivo, Opdualag, Yervoy
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
KEY FEATURE
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
